GFG Capital’s Gilead Sciences GILD Stock Holding History

GFG Capital’s Portfolio GILD Stock Details GILD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-139	Closed	-$15.4K	–	169
2025 Q2	$15.4K	Buy	+139	New	+$14.8K	﹤0.01%	173

Other funds holding GILD

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

GFG Capital's GILD Position: Q3 2025 in Review

GFG Capital sold out of Gilead Sciences (GILD) in Q3 2025, closing a stake of 139 shares — an estimated $15.4K sold.

GFG Capital first reported a position in GILD in Q2 2025 and held it in 1 quarter. The position peaked at $15.4K in Q2 2025. 2,026 funds tracked by Wall St. Rank hold GILD as of Q3 2025.

GFG Capital reported no remaining Gilead Sciences position as of Q3 2025 after selling out during the quarter.
GFG Capital sold 139 Gilead Sciences shares in Q3 2025, an estimated $15.4K.
GFG Capital first reported a position in Gilead Sciences in Q2 2025 and held it in 1 quarter.
GFG Capital's Gilead Sciences position peaked at $15.4K in Q2 2025.
2,026 funds tracked by Wall St. Rank held Gilead Sciences as of Q3 2025.

Based on GFG Capital's 13F filing for Q3 2025, filed 7 Oct 2025.